OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.023
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy